Zosano Pharma Corporation (ZSAN) versus Opexa Therapeutics (ACER) Financial Contrast

Zosano Pharma Corporation (NASDAQ: ZSAN) and Opexa Therapeutics (NASDAQ:ACER) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.


This table compares Zosano Pharma Corporation and Opexa Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zosano Pharma Corporation N/A -169.79% -94.28%
Opexa Therapeutics N/A -108.02% -88.85%

Valuation and Earnings

This table compares Zosano Pharma Corporation and Opexa Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Zosano Pharma Corporation $310,000.00 87.19 -$29.83 million ($1.17) -0.59
Opexa Therapeutics $2.90 million 39.48 -$7.97 million ($5.75) -3.09

Opexa Therapeutics has higher revenue and earnings than Zosano Pharma Corporation. Opexa Therapeutics is trading at a lower price-to-earnings ratio than Zosano Pharma Corporation, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

22.4% of Zosano Pharma Corporation shares are held by institutional investors. Comparatively, 33.6% of Opexa Therapeutics shares are held by institutional investors. 3.0% of Zosano Pharma Corporation shares are held by company insiders. Comparatively, 6.9% of Opexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Zosano Pharma Corporation and Opexa Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zosano Pharma Corporation 0 0 2 0 3.00
Opexa Therapeutics 0 0 0 0 N/A

Zosano Pharma Corporation currently has a consensus price target of $3.50, indicating a potential upside of 410.95%. Given Zosano Pharma Corporation’s higher probable upside, analysts plainly believe Zosano Pharma Corporation is more favorable than Opexa Therapeutics.

Risk & Volatility

Zosano Pharma Corporation has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Opexa Therapeutics has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500.


Opexa Therapeutics beats Zosano Pharma Corporation on 6 of the 11 factors compared between the two stocks.

Zosano Pharma Corporation Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Opexa Therapeutics Company Profile

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply